57
Participants
Start Date
March 31, 2005
Primary Completion Date
September 30, 2009
Study Completion Date
November 30, 2009
Degarelix
Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
State College Urologic Association, State College
Virginia Urology Center, Richmond
The Urology Center, Greensboro
South Florida Medical Research, Aventura
SW Florida Urological Associates, Fort Myers
Urology Centers of Alabama, Homewood
Northeast Indiana Research, LLC, Fort Wayne
Regional Urology, Shreveport
Urology San Antonio Research, San Antonio
Urology Associate PC', Denver
Western Clinical Research, Torrance
West Coast Clinical Research, Tarzana
Advanced Urology Medical Center, Anaheim
Investigational site, Seattle
Lawrenceville Urology, Lawrenceville
University Urological Research Institute, Providence
University of Vermont, Dept of Surgery, South Burlington
Can-Med Clinical Research, Inc., Victoria
The Male and Female Health and Research Centers, Barrie
Brantford Urology Research, Brantford
Burlington Professional Care, Burlington
The Female/Male Health Centres, Oakville
Lead Sponsor
Ferring Pharmaceuticals
INDUSTRY